文献速递儿科与产科急症重症综合管理与镇静镇痛

地塞米松、泼尼松龙与甲泼尼龙使用与极早产儿2岁神经发育结局

Dexamethasone, Prednisolone, and Methylprednisolone Use and 2-Year Neurodevelopmental Outcomes in Extremely Preterm Infants.
PubMed 文献 · JAMA Netw Open · 2022-03-01
一句话结论极早产儿地塞米松疗程超过14天与2岁BSID-III运动评分低7.4分、语言评分低5.8分相关,作者认为长疗程和高累积剂量与更差神经发育评分相关。

该研究为PENUT随机临床试验的二次队列分析,纳入美国19个站点、30个NICU中出生孕24 0/7至27 6/7周、存活出院的828例极早产儿,其中312例(38%)在NICU期间暴露于至少1种目标糖皮质激素。暴露组出生体重更低(718 g vs 868 g)、出生孕周更早(25周 vs 26周)。校正混杂因素后,地塞米松疗程超过14天者2岁时BSID-III运动域评分较未暴露者低7.4分(95%CI -12.3至-2.5,P=0.003)、语言域低5.8分(95%CI -10.9至-0.6,P=0.03)。作者认为长疗程和高累积剂量地塞米松与校正年龄2岁时更差神经发育评分相关,暴露与未暴露婴儿临床状况的潜在未测量差异可能影响结果。

要点

  • 828例存活出院的极早产儿中312例(38%)在NICU期间暴露于至少1种目标糖皮质激素,279例用地塞米松、137例用泼尼松龙或甲泼尼龙、79例两者均用。
  • 地塞米松中位起始日为生后29(20-44)天,中位总暴露10(5-15)天,中位累积剂量1.3(0.9-2.8)mg/kg。
  • 泼尼松龙或甲泼尼龙中位起始日为生后53(30-90)天,中位总暴露13(6-25)天。
  • 校正混杂因素后,地塞米松疗程超过14天者2岁BSID-III运动域评分较未暴露者低7.4分(95%CI -12.3至-2.5,P=0.003)。
  • 地塞米松疗程超过14天者2岁BSID-III语言域评分较未暴露者低5.8分(95%CI -10.9至-0.6,P=0.03)。

适用人群与场景

  • 美国19个参与站点、30个NICU中出生孕24 0/7至27 6/7周、2013年12月至2016年9月出生、存活出院的828例极早产儿(403例[49%]为女孩;中位[IQR]孕周26[25-27]周)。
  • 为PENUT随机临床试验的二次队列分析,分析在2021年2月至2022年1月进行。

诊断标准与关键阈值

  • 暴露定义为NICU期间使用地塞米松、泼尼松龙或甲泼尼龙中的至少1种;评估地塞米松累积剂量及地塞米松和泼尼松龙或甲泼尼龙的治疗持续时间。
  • 神经发育结局在校正年龄2岁时采用贝利婴幼儿发展量表第三版(BSID-III)评估。

研究设计与关键结果

  • 研究类型为PENUT随机临床试验的二次队列分析,纳入19个站点828例存活出院的极早产儿;312例(38%)暴露于至少1种目标糖皮质激素,其中279例暴露于地塞米松、137例暴露于泼尼松龙或甲泼尼龙、79例两者均暴露。
  • 暴露组与未暴露组比较:出生体重更低(均值[SD] 718[168] g vs 868[180] g),出生孕周更早(均值[SD] 25[1]周 vs 26[1]周)。
  • 地塞米松中位(IQR)起始日为29(20-44)天,中位总暴露天数为10(5-15)天,中位累积剂量为1.3(0.9-2.8)mg/kg;泼尼松龙或甲泼尼龙中位起始日为53(30-90)天,中位总暴露天数为13(6-25)天。
  • 校正潜在混杂因素后,地塞米松疗程超过14天与更差神经发育结局相关:BSID-III运动域评分较未暴露婴儿低7.4分(95%CI -12.3至-2.5,P=0.003),语言域评分低5.8分(95%CI -10.9至-0.6,P=0.03)。

证据类型、等级与局限

  • 证据类型:随机临床试验(PENUT)的二次队列分析。
  • 局限:暴露与未暴露婴儿临床状况的潜在未测量差异可能影响结果;作者指出改进治疗标准化和适应证记录将有助于重复研究。

对床旁实践的改变

  • 作者认为长疗程和高累积剂量地塞米松与校正年龄2岁时更差神经发育评分相关;暴露与未暴露婴儿临床状况的潜在未测量差异可能影响该结果。
  • 作者指出改进治疗标准化和适应证记录将有助于重复研究。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Practice variability exists in the use of corticosteroids to treat or prevent bronchopulmonary dysplasia in extremely preterm infants, but there is limited information on longer-term impacts.

OBJECTIVE: To describe the use of corticosteroids in extremely preterm infants and evaluate the association with neurodevelopmental outcomes.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study was a secondary analysis of data from the Preterm Erythropoietin Neuroprotection (PENUT) randomized clinical trial, conducted at 19 participating sites and 30 neonatal intensive care units (NICUs) in the US. Inborn infants born between 24 0/7 and 27 6/7 weeks gestational age between December 2013 and September 2016 were included in analysis. Data analysis was conducted between February 2021 and January 2022.

EXPOSURES: Cumulative dose of dexamethasone and duration of therapy for dexamethasone and prednisolone or methyl prednisolone were evaluated.

MAIN OUTCOMES AND MEASURES: Demographic and clinical characteristics were described in infants who did or did not receive corticosteroids of interest and survived to discharge. Neurodevelopmental outcomes at 2 years of age were evaluated using the Bayley Scales of Infant Development-Third Edition (BSID-III) at corrected age 2 years.

RESULTS: A total of 828 extremely preterm infants (403 [49%] girls; median [IQR] gestational age, 26 [25-27] weeks) born at 19 sites who survived to discharge were included in this analysis, and 312 infants (38%) were exposed to at least 1 corticosteroid of interest during their NICU stay, including 279 exposed to dexamethasone, 137 exposed to prednisolone or methylprednisolone, and 79 exposed to both. Exposed infants, compared with nonexposed infants, had a lower birth weight (mean [SD], 718 [168] g vs 868 [180] g) and were born earlier (mean [SD] gestational age, 25 [1] weeks vs 26 [1] weeks). The median (IQR) start day was 29 (20-44) days for dexamethasone and 53 (30-90) days for prednisolone or methylprednisolone. The median (IQR) total days of exposure was 10 (5-15) days for dexamethasone and 13 (6-25) days for prednisolone or methylprednisolone. The median (IQR) cumulative dose of dexamethasone was 1.3 (0.9-2.8) mg/kg. After adjusting for potential confounders, treatment with dexamethasone for longer than 14 days was associated with worse neurodevelopmental outcomes, with mean scores in BSID-III 7.4 (95% CI, -12.3 to -2.5) points lower in the motor domain (P = .003) and 5.8 (95% CI, -10.9 to -0.6) points lower in the language domain (P = .03), compared with unexposed infants.

CONCLUSIONS AND RELEVANCE: These findings suggest that long duration and higher cumulative dose of dexamethasone were associated with worse neurodevelopmental scores at corrected age 2 years. Potential unmeasured differences in the clinical conditions of exposed vs unexposed infants may contribute to these findings. Improved standardization of treatment and documentation of indications would facilitate replication studies.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Puia-Dumitrescu M, Wood TR, Comstock BA, et al. Dexamethasone, Prednisolone, and Methylprednisolone Use and 2-Year Neurodevelopmental Outcomes in Extremely Preterm Infants. JAMA Netw Open. 2022. PMID: 35275165. doi:10.1001/jamanetworkopen.2022.1947

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。